NASDAQ:QTNT Quotient Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Quotient Limited Please log in to your account or sign up in order to add this asset to your watchlist. $0.25 +0.00 (+0.16%) (As of 06/29/2022 11:41 AM ET) Add Compare Share Today's Range$0.24▼$0.2650-Day Range$0.25▼$0.7952-Week Range$0.24▼$4.04Volume87,992 shsAverage Volume971,291 shsMarket Capitalization$25.69 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive QTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter. Email Address QTNT Stock Forecast (MarketRank)Overall MarketRank™2.14 out of 5 starsMedical Sector498th out of 1,433 stocksDiagnostic Substances Industry5th out of 27 stocksAnalyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingQuotient has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.25, Quotient has a forecasted upside of 809.1% from its current price of $0.25.Amount of Analyst CoverageQuotient has only been the subject of 2 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesQuotient has received 302 “outperform” votes. (Add your “outperform” vote.)Underperform VotesQuotient has received 182 “underperform” votes. (Add your “underperform” vote.)Community SentimentQuotient has received 62.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote “Outperform” if you believe QTNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldQuotient does not currently pay a dividend.Dividend GrowthQuotient does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quotient insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.40% of the stock of Quotient is held by insiders.Percentage Held by Institutions77.47% of the stock of Quotient is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Quotient is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quotient is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Quotient (NASDAQ:QTNT)Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Read More QTNT Stock News HeadlinesJune 29, 2022 | americanbankingnews.comQuotient (NASDAQ:QTNT) Price Target Cut to $1.50June 28, 2022 | businessinsider.comThe most disproportionately popular job in biggest US cities - Business InsiderJune 25, 2022 | finance.yahoo.comQuotient Limited Announces Pricing of Underwritten Offering - Yahoo FinanceJune 25, 2022 | msn.comEarnings Preview For QuotientJune 25, 2022 | seekingalpha.comQuotient stock slumps on pricing $20M share offeringJune 25, 2022 | nasdaq.comQuotient (QTNT) Reports Q4 Loss, Tops Revenue EstimatesJune 24, 2022 | seekingalpha.comQuotient GAAP EPS of -$1.23 beats by $0.03, revenue of $38.51M beats by $1.62M (NASDAQ:QTNT) - Seeking AlphaJune 24, 2022 | seekingalpha.comQuotient stock slumps on pricing $20M share offering - Seeking AlphaJune 24, 2022 | benzinga.comZendesk, Quotient, + 40 Stocks Moving In Friday’s Mid-Day Session - Benzinga - BenzingaJune 24, 2022 | globenewswire.comQuotient Limited Announces Pricing of Underwritten Offering - GlobeNewswireJune 24, 2022 | finance.yahoo.comQuotient Limited Announces Pricing of Underwritten OfferingJune 23, 2022 | globenewswire.comQuotient Limited Announces Proposed Amendments to Senior Secured Notes - GlobeNewswireJune 23, 2022 | benzinga.comEarnings Preview For Quotient - Benzinga - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTNT CUSIPN/A CIK1596946 Webwww.quotientbd.com Phone(122) 716-9800FaxN/AEmployees426Year FoundedN/ACompany Calendar Last Earnings6/24/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$2.25 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+499.0%Consensus RatingHold Rating Score (0-4)2 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.210010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125.13 million Net Margins-317.38% Pretax Margin-357.83% Return on EquityN/A Return on Assets-49.90% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio4.83 Sales & Book Value Annual Sales$38.51 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-0.72Miscellaneous Outstanding Shares102,599,000Free Float92,955,000Market Cap$25.69 million OptionableOptionable Beta2.72 Quotient Frequently Asked Questions Should I buy or sell Quotient stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Quotient stock. View analyst ratings for Quotient or view top-rated stocks. What is Quotient's stock price forecast for 2022? 3 Wall Street analysts have issued 12-month price targets for Quotient's stock. Their QTNT stock forecasts range from $1.50 to $3.00. On average, they anticipate Quotient's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 798.6% from the stock's current price. View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts. How has Quotient's stock performed in 2022? Quotient's stock was trading at $2.59 at the beginning of 2022. Since then, QTNT shares have decreased by 90.3% and is now trading at $0.2504. View the best growth stocks for 2022 here. When is Quotient's next earnings date? Quotient is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Quotient. How were Quotient's earnings last quarter? Quotient Limited (NASDAQ:QTNT) announced its earnings results on Friday, June, 24th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.09. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. View Quotient's earnings history. What guidance has Quotient issued on next quarter's earnings? Quotient updated its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.50 million-$38.50 million, compared to the consensus revenue estimate of $36.89 million. Who are Quotient's key executives? Quotient's management team includes the following people: Mr. Manuel O. Mendez, CEO & Director (Age 54)Mr. Ali Kiboro, Chief Financial OfficerMs. Vittoria Bonasso, Head of Fin., Group Controller & Principal Accounting Officer (Age 46)Dr. Michael Hausmann, Chief Technology OfficerDr. Christine Ginocchio, Chief Scientific & Medical OfficerMr. Christian Albrich, Chief People Officer (Age 58)Mr. Mohammad El Khoury, Chief Commercial OfficerMr. Esteban Uriarte, Chief Manufacturing Operations Officer Who are some of Quotient's key competitors? Some companies that are related to Quotient include OncoCyte (OCX), MyMD Pharmaceuticals (MYMD), Aspira Women's Health (AWH), Lucira Health (LHDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Biomerica (BMRA), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), ARCA biopharma (ABIO), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSF) and StageZero Life Sciences (GNWSD). View all of QTNT's competitors. What other stocks do shareholders of Quotient own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE). What is Quotient's stock symbol? Quotient trades on the NASDAQ under the ticker symbol "QTNT." Who are Quotient's major shareholders? Quotient's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (8.89%), BlackRock Inc. (5.25%), Clearbridge Investments LLC (4.15%), TimesSquare Capital Management LLC (2.65%), Vanguard Group Inc. (1.72%) and State Street Corp (1.46%). Company insiders that own Quotient stock include Edward Farrell, Jeremy Stackawitz, Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd. View institutional ownership trends for Quotient. Which institutional investors are selling Quotient stock? QTNT stock was sold by a variety of institutional investors in the last quarter, including Walleye Capital LLC, Walleye Capital LLC, BlackRock Inc., JPMorgan Chase & Co., TimesSquare Capital Management LLC, Vanguard Group Inc., and Northern Trust Corp. View insider buying and selling activity for Quotient or view top insider-selling stocks. Which institutional investors are buying Quotient stock? QTNT stock was purchased by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, State Street Corp, GSA Capital Partners LLP, and Clearbridge Investments LLC. Company insiders that have bought Quotient stock in the last two years include Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, and Prondzynski Heino Von. View insider buying and selling activity for Quotient or or view top insider-buying stocks. How do I buy shares of Quotient? Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Quotient's stock price today? One share of QTNT stock can currently be purchased for approximately $0.25. How much money does Quotient make? Quotient (NASDAQ:QTNT) has a market capitalization of $25.69 million and generates $38.51 million in revenue each year. The company earns $-125.13 million in net income (profit) each year or ($1.210010) on an earnings per share basis. How many employees does Quotient have? Quotient employs 426 workers across the globe. How can I contact Quotient? Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for Quotient is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at [email protected]. This page (NASDAQ:QTNT) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here